AbbVie signals beyond the news: 62+ signals from 7 sources
The latest AbbVie signal on this page is from Nov 17, 2026 (Patents): "AbbVie Inc. uses JONES DAY as outside IP counsel." The busiest sources: X (Twitter) (15+), LinkedIn (14) and Glassdoor (13).
Public (ABBV)Pharmaceutical Manufacturing10,000+ employeesabbvie.comLinkedIn
Get AbbVie's live signals in Claude or ChatGPT, or by API
What changed at AbbVie this week? Use Autobound signals for abbvie.com.- Signals
- 62+
- Sources
- 7
- Last 90 days
- 46
- Latest
- Nov 17, 2026
Source: Autobound Signal API · 112 signals tracked for AbbVie · updated
Other signals · latest 10
Latest AbbVie signals by source
62+ signals for AbbVie across 7 sources.
Patents · Patent counsel
AbbVie Inc. uses JONES DAY as outside IP counsel.
JONES DAY is the attorney of record on AbbVie Inc.'s recent US patent work, including a grant in 2026-11.
- Law firm
- JONES DAY
- Law firm domain
- jonesday.com
- Matter date
- Nov 17, 2026
Patents · Patent grant
AbbVie was granted a patent for improved risankizumab compositions.
In November 2026 AbbVie patented risankizumab formulations for pharmaceutical use, designed to reduce unwanted proteins, processing additives, and immune reactions.
- Patent title
- Risankizumab compositions
- Grant date
- Nov 17, 2026
- Inventors
- Liqiang Zhou
Glassdoor · Return to office tension
Employee expresses dissatisfaction with mandatory return to office policy
A senior associate in clinical data systems notes that the recent mandate to return to the office is a significant negative factor in their current experience.
- Overall rating
- 4.0 of 5
- CEO approval
- 86%
- Reviews read
- 10
- Review window
- Nov 2, 2026 to Nov 7, 2026
Glassdoor · Sales compensation concerns
Immunology sales staff cite complex and discouraging incentive compensation structures
One representative reports that the payout curve is disproportionate, with employees losing 40 percent of their target incentive payout after falling only slightly short of their goal.
- Overall rating
- 4.0 of 5
- CEO approval
- 86%
- Reviews read
- 10
- Review window
- Nov 2, 2026 to Nov 7, 2026
X (Twitter)
AbbVie shares expert discussion on migraine's global socioeconomic burden, citing Brazil cost figures.
#DYK migraine's socioeconomic burden in Brazil alone in 2018 – 2022 was as much as $148.5 billion? Dr. Malina Müller and Dr. Welber Sousa Oliveira discuss the global socioeconomic impact of migraine. Learn more about migraine and the socioeconomic burden: https://t.co/mse6DsDowq https://t.co/0KUh0ULnAs
- Account
- @abbvie
- Views
- 1,138
- Likes
- 4
- Reposts
- 0
Reddit · Product change
AbbVie discontinued its Phase 2 solid tumor drug livmoniplimab, tested in combination with budigalimab, citing limited clinical benefit.
Post: "AbbVie abandons phase 2 solid tumor drug over ‘limited benefit’"
- Subreddit
- r/biotech
- Upvotes
- 49
- Comments
- 14
- Sentiment
- Negative
X (Twitter)
AbbVie invites attendees to booth #221 and a Product Theater presentation on clinical evidence.
Attending? Stop by booth #221 to meet our team and learn about our Product Theater presentation "Clinical and Real-World Evidence: A Comprehensive Perspective in MDD (adjunctive) Patients and Bipolar I Patients": https://t.co/vBBnE4DCB1 https://t.co/baXHLRjreO
- Account
- @abbvie
- Views
- 877
- Likes
- 1
- Reposts
- 0
Conference talks
Kinga Bazior (Team & Leadership Trainer, AbbVie) at Code Europe 2026.
- Conference
- Code Europe 2026
- Date
- Sep 14, 2026
- Location
- Online and Warsaw, Poland
- Topics
- AI engineering, data engineering, platform engineering, Kubernetes
Podcasts · Tech adoption
Venture with Grace discusses AbbVie: tech adoption
"We also work with healthcare, right? So companies like Blue Cross Blue Shield or AbbVie, where we do a number of different things. But one example there would be, how do you automate clinical documentation?"
- Podcast
- Venture with Grace
- Episode
- Frank Petterson, Uniphore CTPO on Enterprise AI and Product Leadership
- Speaker
- Frank Petterson
- Speaker role
- Counterparty
LinkedIn
Next week, we’ll be at the 44th Annual J.P.
Next week, we’ll be at the 44th Annual J.P. Morgan Healthcare Conference. Tune in to the live audio webcast of our fireside chat on January 14, available here: https://bit.ly/3N8fbsi $ABBV #JPM26
- Likes
- 2
- Tags
- Pharmaceuticals, Investor Relations, Corporate Strategy
Showing 10 of 62+ signals. The Signal API returns all of them.
Get them with one API callSignal API · MCP
Track AbbVie with the Signal API
One POST /v1/companies/enrich call with abbvie.com returns AbbVie signals from 14 more signal types (reddit-company, podcast-company, glassdoor-company and more), each with its source. Or ask Claude through MCP.
2 credits per signal returned; zero-result calls are free. Endpoint reference
curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{
"domain": "abbvie.com",
"signal_types": ["reddit-company","podcast-company","glassdoor-company",
"product-reviews","linkedin-post-company","twitter-company-posts",
"youtube-company","website-intelligence","patents-company",
"federal-contract-award","conference-speaker","hackernews",
"producthunt-launch","seo-traffic"],
"limit": 20
}'Bulk data
Need these signals for 10,000+ companies?
Get a free sample file or a bulk feed (API, GCS push, flat file).
Same industry
Other signals at related companies
Questions about AbbVie other signals
What signals does Autobound track for AbbVie besides news and filings?
What are people saying about AbbVie online?
What do employees say about working at AbbVie?
Has AbbVie been granted patents recently?
Page updated , the date of the newest row on this page.
Source. Reddit, podcasts, Glassdoor, product reviews, LinkedIn, X, YouTube, company websites, patents, federal contracts, conference talks, Hacker News, Product Hunt, web traffic and employee growth, from the Signal API.
Method. The latest 15 signals per source from the last 12 months. Posts that do not name the company, replies, repeats and unreadable rows are removed. Traffic and headcount keep their newest measure.
Data as of .